Global Migraine Market: Industry Analysis & Outlook (2017-2021) - Koncept Analytics

1
Industry Research by Koncept Analytics
Global Migraine Market Industry Analysis
Outlook -----------------------------------------
(2017-2021)
May 2017
2
Executive Summary
Migraine is a chronic neurovascular disorder
characterized by severe recurrent headaches. It
is one of the most common and most prevalent
disabling neurological conditions, characterized
by episodes often called migraine attacks. They
are quite different from regular headaches which
are non-migrainous. Migraineurs generally have a
lower threshold to triggers that might cause
neuronal hyperexcitability, including sleep
disturbances, environmental or emotional
challenges, alcohol exposure, diet, and hormonal
cycles/changes, among others. Migraine attacks
can cause significant pain for hours to days and
can be so severe that the pain is disabling.
Migraine headache is typically throbbing,
unilateral (one sided), and is aggravated by
physical activity. It typically presents with
additional symptoms in addition to headache pain,
including nausea, and sensitivity to light and/or
sound. Depending on symptoms, migraine is broadly
classified into two categories, Chronic and
Episodic. Migraines can be treated with two types
of drugs abortive and preventive. Abortive
medications are especially useful for people who
have nausea or vomiting related to their
migraine, and they work quickly. Preventive
treatment is considered if migraine occurs
frequently, typically more than one migraine per
week, or if migraine symptoms are severe. The
global migraine market is set to experience
favourable growth driven by factors such as
increasing female population increasing
cigarette consumption. Further, the scope of
growth for this market will be broadened by
rising healthcare expenditure and accelerating
economic growth. However, growth of this budding
market will be hindered by limitations of current
migraine therapies, regulatory challenges and
high cost associated with migraine drugs. The
report Global Migraine Market Industry Analysis
Outlook (2017-2021) analyses the development
of this market, with focus majorly on the U.S.
market. The major trends, growth drivers as well
as issues being faced by the market are discussed
in detail in this report. The four major players
Amgen Inc., Eli Lilly and Company, Teva
Pharmaceuticals Alder Biopharmaceuticals are
being profiled along with their key financials
and strategies for growth. The report contains a
comprehensive analysis of the global migraine
market along with the study of the regional
markets.
3
Rising female population and increasing cigarette
consumption supported the growth of migraine
market.
Global Migraine Market by Value (2012-2016)

• The global migraine market reached US ..billion
  in the year 2016, increasing from US ..billion
  in 2012, recording growth at a CAGR of .. for
  the period spanning 2012-2016.
• The global migraine market is expected to reach
  US ..billion by the year 2021, increasing from
  US ..billion in the year 2016, recording growth
  at a CAGR of .. for the period spanning
  2017-2021.
• On the basis of drug segmentation for migraine
  treatment, Triptans held the .. share followed
  by DHE and other drugs with .. shares
  respectively.

Global Migraine Market by Drug Type (2016)
T Global Migraine Market Forecast by Value
(2017-2021)
4
Accelerating economic growth and rising
healthcare expenditure will drive the market for
migraine globally..
The U.S. Total Migraine Population (2016-2021)

• In U.S., the total migraine population is
  estimated to reach ..million by the year 2021,
  increasing from ..million in the year 2016,
  recording growth at a CAGR of .. for the period
  spanning 2016-2021.
• Out of the total migraine population in the U.S.,
  ..million were at a high risk of developing
  cardiovascular disease. Such population is
  expected to reach ..million by the year 2021 and
  ..million people were at a lower risk of
  developing cardiovascular disease in 2016, which
  is estimated to reach ..million by the end of
  year 2021.
• In Europe, the total migraine and diagnosed
  population is anticipated to reach ..million by
  the year 2021, increasing from ..million in the
  year 2016, recording growth at a CAGR of .. for
  the period spanning 2016-2021.

Europe Total Migraine and Diagnosed
Population (2016-2021)
The U.S. Migraine Population with CV Risk
Factors (2016-2021)
5
Disclaimer
Contact Us
This is a licensed product of Koncept Analytics.
You cannot reproduce, publish, distribute,
publicly display, sell or create other works from
this report or use them in any way for commercial
purpose without our prior permission. Further,
you cannot copy this material, by any means
(including electronic copies), for distribution
to others unless you have purchased the corporate
license of this report. We believe the sources
are reliable, but Koncept Analytics does not
warranty the accuracy or completeness of the
data. The data presented in the report is updated
at the publication date but is subject to change
at subsequent releases. All possible efforts have
been made to ensure accuracy of data. However,
investors should not completely rely on the
information given in this report and must make
decisions based on their own investment strategy,
risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T
91-120-4130959 M 91-9811715635
vikas_at_konceptanalytics.com
www.konceptanalytics.com